• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Recent Advances in the Study of 2-(2,4-Dibromophenoxy)acetohydrazide (CAS: 141244-86-2) in Chemical Biology and Pharmaceutical Research

The compound 2-(2,4-Dibromophenoxy)acetohydrazide (CAS: 141244-86-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This hydrazide derivative, characterized by its unique bromophenoxy moiety, has been the subject of several studies aimed at elucidating its biological activities, mechanisms of action, and potential therapeutic uses. The following sections provide a comprehensive overview of the latest research findings related to this compound, highlighting its significance in contemporary scientific investigations.

Recent studies have focused on the synthesis and structural optimization of 2-(2,4-Dibromophenoxy)acetohydrazide to enhance its pharmacological properties. Researchers have employed advanced synthetic techniques, including microwave-assisted synthesis and green chemistry approaches, to improve yield and purity. Structural modifications, such as the introduction of additional functional groups, have been explored to increase the compound's bioavailability and target specificity. These efforts have yielded promising results, with several derivatives demonstrating enhanced activity in preliminary biological assays.

In vitro and in vivo studies have revealed that 2-(2,4-Dibromophenoxy)acetohydrazide exhibits notable antimicrobial and anticancer properties. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that the compound effectively inhibits the growth of multidrug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve disruption of bacterial cell membrane integrity and inhibition of key enzymatic pathways. Additionally, the compound has shown cytotoxic effects against various cancer cell lines, with particular efficacy observed in breast and lung cancer models. These findings suggest its potential as a lead compound for the development of novel antimicrobial and anticancer agents.

Further investigations into the molecular mechanisms underlying the biological activities of 2-(2,4-Dibromophenoxy)acetohydrazide have employed computational modeling and high-throughput screening techniques. Molecular docking studies have identified potential binding interactions with bacterial DNA gyrase and human topoisomerase II, providing insights into its dual antimicrobial and anticancer effects. Moreover, transcriptomic and proteomic analyses have revealed that the compound modulates the expression of genes involved in oxidative stress response and apoptosis, further elucidating its multifaceted pharmacological profile.

Despite these promising findings, challenges remain in the clinical translation of 2-(2,4-Dibromophenoxy)acetohydrazide. Issues such as solubility, stability, and potential toxicity need to be addressed through further preclinical studies. Recent efforts have focused on formulating the compound into nanoparticle-based delivery systems to enhance its pharmacokinetic properties. Preliminary results from animal studies indicate that such formulations can improve bioavailability and reduce off-target effects, paving the way for future clinical trials.

In conclusion, 2-(2,4-Dibromophenoxy)acetohydrazide (CAS: 141244-86-2) represents a promising candidate for drug development, with demonstrated antimicrobial and anticancer activities. Ongoing research aims to optimize its chemical structure, elucidate its mechanisms of action, and overcome translational challenges. The compound's unique properties and versatile applications underscore its potential to contribute significantly to the advancement of chemical biology and pharmaceutical science.

• 5402-32-4(2-(2-bromophenoxy)propanehydrazide)
• 315248-38-5(2-(1-Bromo-2-naphthyl)oxyacetohydrazide)
• 328085-17-2(2-(2-Bromophenoxy)acetohydrazide)
• 16738-00-4(2-(4-Bromophenoxy)acetohydrazide)
• 356100-06-6(2-(2,4-Dibromo-6-methylphenoxy)acetohydrazide)
• 327070-44-0(2-(4-Bromo-3-methylphenoxy)acetohydrazide)
• 6079-89-6(Octadecanoic acid,2,2-dimethylhydrazide)
• 52570-06-6(2-(2-Bromo-4-tert-butylphenoxy)acetohydrazide)
• 308292-49-1(2-(3-Bromophenoxy)acetohydrazide)
• 438219-93-3(2-(6-Bromo-2-naphthyl)oxyacetohydrazide)